Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
The design, synthesis, and in vitro activity of a series of novel 5-ethynyl-2-aryloxybenzylamine-based histamine H(3) ligands that are also serotonin reuptake transporters is described.
Letavic
Michael A
MA
Johnson & Johnson Pharmaceutical Research & Development LLC, 3210 Merryfield Row, San Diego, CA 92121, USA. mletavic@prdus.jnj.com
Stocking
Emily M
EM
Barbier
Ann J
AJ
Bonaventure
Pascal
P
Boggs
Jamin D
JD
Lord
Brian
B
Miller
Kirsten L
KL
Wilson
Sandy J
SJ
Carruthers
Nicholas I
NI
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology; D001596:Benzylamines / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D015195:Drug Design; D006633:Histamine Antagonists / Q000138:chemical synthesis* / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008956:Models, Chemical; D011485:Protein Binding; D051381:Rats; D018100:Receptors, Histamine H3 / Q000737:chemistry*; D017367:Selective Serotonin Reuptake Inhibitors / Q000737:chemistry / Q000494:pharmacology*
D000928:Antidepressive Agents; D001596:Benzylamines; D006633:Histamine Antagonists; D018100:Receptors, Histamine H3; D017367:Selective Serotonin Reuptake Inhibitors